​
​

Aclaris Therapeutics (ACRS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Aclaris Therapeutics Revenue Highlights

Latest Revenue (Y)

$31.25M

Latest Revenue (Q)

$4.35M

Main Segment (Y)

License and Service

Aclaris Therapeutics Revenue by Period

Aclaris Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$31.25M5.03%
2022-12-31$29.75M340.05%
2021-12-31$6.76M4.30%
2020-12-31$6.48M53.35%
2019-12-31$4.23M-58.11%
2018-12-31$10.09M499.58%
2017-12-31$1.68M100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Aclaris Therapeutics generated $31.25M in revenue during NA 2023, up 5.03% compared to the previous quarter, and up 309.67% compared to the same period a year ago.

Aclaris Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$4.35M57.12%
2024-06-30$2.77M15.35%
2024-03-31$2.40M-86.35%
2023-12-31$17.57M89.29%
2023-09-30$9.28M396.63%
2023-06-30$1.87M-26.07%
2023-03-31$2.53M-67.39%
2022-12-31$7.75M-59.23%
2022-09-30$19.02M1144.63%
2022-06-30$1.53M5.16%
2022-03-31$1.45M-3.20%
2021-12-31$1.50M-9.52%
2021-09-30$1.66M-9.05%
2021-06-30$1.82M2.64%
2021-03-31$1.78M12.47%
2020-12-31$1.58M9.04%
2020-09-30$1.45M-29.18%
2020-06-30$2.05M45.42%
2020-03-31$1.41M28.49%
2019-12-31$1.09M11.39%
2019-09-30$983.00K-83.24%
2019-06-30$5.87M16.35%
2019-03-31$5.04M37.39%
2018-12-31$3.67M125.37%
2018-09-30$1.63M-55.71%
2018-06-30$3.68M228.80%
2018-03-31$1.12M11.91%
2017-12-31$999.00K46.05%
2017-09-30$684.00K100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30--

Aclaris Therapeutics generated $4.35M in revenue during Q3 2024, up 57.12% compared to the previous quarter, and up 232.53% compared to the same period a year ago.

Aclaris Therapeutics Revenue Breakdown

Aclaris Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Contract research$3.04M$4.39M$5.83M--
License and Service$28.21M$25.10M---
Other-$257.00K---
Other revenue--$931.00K--
Product---$424.00K-
Rhofade Product---$424.00K-
Laboratory Research Revenue----$4.23M

Aclaris Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (90.29%), and Contract research (9.71%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
License and Service$3.70M$1.74M$25.58M$994.00K$1.64M$6.72M$17.90M-------------
Contract research$645.00K$657.00K$1.27M$875.00K$889.00K$866.00K$1.09M$1.22M$1.22M$1.27M----------
Other-----$165.00K$30.00K-------------
Other revenue-------$310.00K$232.00K$227.00K----------
Other Revenue----------$244.00K$218.00K$242.00K$167.00K$118.00K$193.00K$218.00K---
Laboratory Research Revenue----------$1.42M$1.61M$1.53M$1.41M$1.33M$1.85M$1.19M$1.09M$983.00K-
Eskata Product-------------------$272.00K
Product-------------------$4.98M
Rhofade Product-------------------$4.71M

Aclaris Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (85.16%), and Contract research (14.84%).

Aclaris Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
IQVIQVIA$14.98B$3.90B
ICLRICON Public Limited Company$8.12B$2.09B
QGENQiagen$1.97B$458.80M
MEDPMedpace$1.89B$533.32M
RDNTRadNet$1.62B$461.14M
SHCSotera Health Company$1.05B$285.47M
NEOGNeogen$924.22M$216.96M
MYGNMyriad Genetics$678.40M$191.90M
GTHGenetron$650.71M$201.32M
CSTLCastle Biosciences$219.79M$85.78M
OLKOlink AB (publ)$169.91M$28.59M
BDSXBiodesix$49.09M$18.15M
ACRSAclaris Therapeutics$31.25M$4.35M
PREPrenetics Global$21.74M$6.41M

ACRS Revenue FAQ

What is Aclaris Therapeutics’s yearly revenue?

Aclaris Therapeutics's yearly revenue for 2023 was $31.25M, representing an increase of 5.03% compared to 2022. The company's yearly revenue for 2022 was $29.75M, representing an increase of 340.05% compared to 2021. ACRS's yearly revenue for 2021 was $6.76M, representing an increase of 4.30% compared to 2020.

What is Aclaris Therapeutics’s quarterly revenue?

Aclaris Therapeutics's quarterly revenue for Q3 2024 was $4.35M, a 57.12% increase from the previous quarter (Q2 2024), and a -53.18% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.77M, a 15.35% increase from the previous quarter (Q1 2024), and a 47.99% increase year-over-year (Q2 2023). ACRS's quarterly revenue for Q1 2024 was $2.4M, a -86.35% decrease from the previous quarter (Q4 2023), and a -5.14% decrease year-over-year (Q1 2023).

What is Aclaris Therapeutics’s revenue growth rate?

Aclaris Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 362.19%, and for the last 5 years (2019-2023) was 639.27%.

What are Aclaris Therapeutics’s revenue streams?

Aclaris Therapeutics's revenue streams in c 23 are Contract research, and License and Service. Contract research generated $3.04M in revenue, accounting 9.71% of the company's total revenue, down -30.94% year-over-year. License and Service generated $28.21M in revenue, accounting 90.29% of the company's total revenue, up 12.41% year-over-year.

What is Aclaris Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Aclaris Therapeutics was License and Service. This segment made a revenue of $28.21M, representing 90.29% of the company's total revenue.